Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Krishnamurthi S et al. | Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. | 1984 | Biochem. Pharmacol. | pmid:6091666 |
Kamitani T et al. | Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. | 1984 | Eur. J. Pharmacol. | pmid:6144557 |
Tokumura A et al. | Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. | 1984 | J. Pharm. Pharmacol. | pmid:6144763 |
Pirotzky E et al. | Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. | 1984 | Kidney Int. | pmid:6144811 |
Colditz IG and Movat HZ | Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. | 1984 | J. Immunol. | pmid:6088633 |
Kazimierczak W et al. | Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. | 1984 | Am. Rev. Respir. Dis. | pmid:6201094 |
Malpass TW et al. | The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. | 1984 | J. Thorac. Cardiovasc. Surg. | pmid:6231433 |
Fouque F and Vargaftig BB | Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. | 1984 | Br. J. Pharmacol. | pmid:6439269 |
Karlsson G and Pipkorn U | Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. | 1984 | Eur. J. Clin. Pharmacol. | pmid:6439565 |
Sänze JU et al. | On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. | 1984 | Biomed. Biochim. Acta | pmid:6440544 |
Sills RH | Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. | 1984 | Am J Pediatr Hematol Oncol | pmid:6442830 |
Lartigue-Mattei C et al. | Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. | 1984 | Agents Actions | pmid:6532184 |
Kulikov VI et al. | [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. | 1984 | Biokhimiia | pmid:6542803 |
Chilton FH et al. | 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. | 1984 | J. Biol. Chem. | pmid:6434535 |
Doebber TW et al. | Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6517949 |
Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
Oxholm P et al. | Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. | 1984 | Allergy | pmid:6528957 |
Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
Colditz IG and Movat HZ | Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. | 1984 | J. Immunol. | pmid:6470487 |
Patterson R et al. | Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. | 1984 | J. Lab. Clin. Med. | pmid:6470563 |
Caramelo C et al. | Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6732788 |
Lenihan DJ and Lee TC | Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6732789 |
Kasuya Y et al. | Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. | 1984 | Can. J. Physiol. Pharmacol. | pmid:6733593 |
Page CP et al. | Platelets and bronchospasm. | 1984 | Int. Arch. Allergy Appl. Immunol. | pmid:6735490 |
Clare KA and Scrutton MC | The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). | 1984 | Eur. J. Biochem. | pmid:6705791 |
Kumar R et al. | A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. | 1984 | J. Lipid Res. | pmid:6707528 |
Pelczar-Wissner CJ et al. | Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. | 1984 | Am. J. Hematol. | pmid:6720685 |
Guay DR and Richard A | Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. | 1984 | Drug Intell Clin Pharm | pmid:6723517 |
Poitevin B et al. | Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. | 1984 | Immunopharmacology | pmid:6724877 |
Kawaguchi H and Yasuda H | Platelet-activating factor stimulates phospholipase in quiescent Swiss mouse 3T3 fibroblast. | 1984 | FEBS Lett. | pmid:6436057 |
Kasuya Y et al. | Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). | 1984 | J. Pharmacobio-dyn. | pmid:6726619 |
Schleimer RP et al. | Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. | 1984 | J. Allergy Clin. Immunol. | pmid:6208229 |
Nishihira J et al. | Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. | 1984 | Lipids | pmid:6527609 |
Gunby P | A new piece for the puzzle of inflammation. | 1984 | JAMA | pmid:6420583 |
Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |
Billah MM and Siegel MI | Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6422930 |
Wodzinowska B and Krajewski T | [Role of blood platelets and their membrane in the process of hemostasis]. | 1984 Jan-Feb | Postepy Hig Med Dosw | pmid:6093087 |
Vemulapalli S et al. | Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. | 1984 Jul-Aug | Hypertension | pmid:6378787 |
Cox CP et al. | VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). | 1984 Mar-Apr | Peptides | pmid:6206481 |
Morris HG | Mechanisms of glucocorticoid action in pulmonary disease. | 1985 | Chest | pmid:2410202 |
Hemmendinger S et al. | [Physiology of the interactions of blood and the blood vessel wall. Role of pharmacologically active lipids]. | 1985 | Arch Mal Coeur Vaiss | pmid:3938941 |
Maes L et al. | In vivo arterial platelet-vessel wall interaction and thrombosis: induction, on-line registration and ultrastructural control. | 1985 | Adv. Exp. Med. Biol. | pmid:3832867 |
Ostermann G et al. | Platelet-stimulating and membranolytic properties of racemic PAF-acether and analogues. | 1985 | Biomed. Biochim. Acta | pmid:4004829 |
Touqui L et al. | Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. | 1985 | Biochem. J. | pmid:4052028 |
Satouchi K et al. | Evidence for production of 1-acyl-2-acetyl-sn-glyceryl-3-phosphorylcholine concomitantly with platelet-activating factor. | 1985 | Biochem. Biophys. Res. Commun. | pmid:4004866 |
Apprill P et al. | Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors. | 1985 | Circulation | pmid:2988822 |
Imbs AB et al. | [Synthesis of a fluorescently-labeled platelet activating factor]. | 1985 | Bioorg. Khim. | pmid:4062993 |
Tokumura A et al. | Gas chromatographic-mass spectrometric analysis of biologically active phospholipids having an sn-2-acetyl group. | 1985 | J. Chromatogr. | pmid:4066848 |
Morley J et al. | PAF and airway hyperreactivity. | 1985 | Lancet | pmid:2863479 |
Morley J et al. | Platelets in asthma. | 1985 | Lancet | pmid:2863708 |